Skip to content
OpenCapital
Get started

Sonoma Pharmaceuticals, Inc. SNOA Q4 2024 earnings

Reported February 5, 2025 · Before market open

Revenue$3.6MMiss by $876.0KDiluted EPS-$0.59Beat by $0.21
Revenue estimate$4.4M
EPS estimate-$0.80

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$5.0M
EPS estimate-$0.30

Versus estimates

Revenue

Q1 2026$5.6MMiss by $4.3KQ4 2025$4.3MMiss by $1.1MQ3 2025$5.6MBeat by $1.3MQ2 2025$4.0MMiss by $315.0KQ1 2025$3.8MMiss by $685.6K
Q4 2024$3.6MMiss by $876.0K

Diluted EPS

Q1 2026-$0.09Beat by $0.15Q4 2025-$0.35Miss by $0.06Q3 2025-$0.13Beat by $0.18Q2 2025-$0.37Beat by $0.14Q1 2025-$0.15Beat by $0.58
Q4 2024-$0.59Beat by $0.21

Ask the moment Sonoma Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Sonoma Pharmaceuticals, Inc. report Q4 2024 earnings?
Sonoma Pharmaceuticals, Inc. (SNOA) reported Q4 2024 earnings on February 5, 2025 before market open.
What were Sonoma Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?
Sonoma Pharmaceuticals, Inc. reported revenue of $3.6M and diluted EPS of $-0.59 for Q4 2024.
Did Sonoma Pharmaceuticals, Inc. beat estimates in Q4 2024?
Revenue missed the consensus estimate of $4.4M by $876.0K. EPS beat the consensus estimate of $-0.80 by $0.21.
Where can I find Sonoma Pharmaceuticals, Inc.'s Q4 2024 SEC filings?
You can read the 10-Q periodic report (0001683168-25-000736) directly on SEC EDGAR. The filing index links above go to sec.gov.